Telomir Pharmaceuticals, Inc.

TELO Nasdaq SEC CIK 1971532
Follow Telomir Pharmaceuticals Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Net income −$705.2K +36% vs same quarter last year
EPS, diluted −$0.01 +66.7% vs same quarter last year
Operating cash flow −$586.4K +36.8% vs same quarter last year
Net income by quarter
−$2.9M
−$2.2M
−$5.1M
−$1.1M
−$2.1M
−$990.9K
−$1.7M
−$705.2K
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income5 fiscal years
−$20M−$15M−$10M−$5M$0FY21FY22FY23FY24FY25
Show the numbers
YearNet income
FY25−$10.4M
FY24−$16.5M
FY23-
FY22−$854.1K
FY21-